Technical Analysis for ARWR - Arrowhead Research Corporation
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Down | Up | Up |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Bollinger Band Squeeze | Range Contraction | 0.00% | |
BB Squeeze Started | Range Contraction | 0.00% | |
20 DMA Support | Bullish | 0.23% | |
Hammer Candlestick | Bullish | 0.23% | |
180 Bullish Setup | Bullish Swing Setup | 0.23% | |
Pocket Pivot | Bullish Swing Setup | 0.23% | |
NR7 | Range Contraction | 1.40% | |
NR7-2 | Range Contraction | 1.40% | |
Down 3 Days in a Row | Weakness | 1.40% | |
Slingshot Bullish | Bullish Swing Setup | -0.80% |
Alert | Time |
---|---|
60 Minute Opening Range Breakdown | about 6 hours ago |
Up 3% | about 10 hours ago |
Up 2% | about 10 hours ago |
10 DMA Support | about 10 hours ago |
Bullish 180 Entry | about 10 hours ago |
Get this analysis on your stocks daily!
- Earnings date: 08/05/2024
Arrowhead Research Corporation Description
Arrowhead Research Corporation operates as a clinical stage therapeutics company. It has development programs in oncology, obesity, and chronic hepatitis B virus (HBV) infection. The company assembles a set of technologies, including Dynamic Polyconjugate platform, a RNA delivery system that addresses multiple organ systems and cell types, promotes multi-log gene knockdown in rodents and non-human primates, and induces endosomal escape; and RONDEL, a RNA delivery system for systemic siRNA delivery, and RNAi-mediated mRNA and protein knockdown in human melanoma patients. It also offers Homing Peptides platform, a library of short peptides for the development of peptide-drug conjugates and companion diagnostics. The company's principal product candidates include Adipotide, an anti-obesity peptide, which is in Phase I clinical trial for disrupting the blood supply that supports unhealthy fat by the targeted induction of apoptosis (cell death) in the vasculature of adipose tissue; ARC-520, an RNAi-based therapeutic to treat chronic HBV infection; and CALAA-01, an RNAi-based therapeutic that has completed a Phase IB clinical trial, which targets solid tumors. Its products also comprise CRLX-101 for NSC lung cancer; and Tubulin Inhibitor for oncology. The company, formerly known as InterActive Group, Inc., was founded in 2003 and is headquartered in Pasadena, California.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Solid Tumors Organ Systems Molecular Biology Infection Obesity Hepatitis B Gene Expression RNA Rna Interference Apoptosis Chronic Hepatitis B Virus Chronic Hbv Infection Rna Therapeutics Si RNA Small Interfering Rna
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 39.83 |
52 Week Low | 20.67 |
Average Volume | 1,102,969 |
200-Day Moving Average | 27.64 |
50-Day Moving Average | 24.42 |
20-Day Moving Average | 25.35 |
10-Day Moving Average | 25.61 |
Average True Range | 1.33 |
RSI (14) | 54.55 |
ADX | 12.38 |
+DI | 30.11 |
-DI | 23.26 |
Chandelier Exit (Long, 3 ATRs) | 23.81 |
Chandelier Exit (Short, 3 ATRs) | 26.34 |
Upper Bollinger Bands | 27.32 |
Lower Bollinger Band | 23.38 |
Percent B (%b) | 0.68 |
BandWidth | 15.54 |
MACD Line | 0.44 |
MACD Signal Line | 0.35 |
MACD Histogram | 0.0902 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 28.12 | ||||
Resistance 3 (R3) | 28.19 | 27.58 | 27.78 | ||
Resistance 2 (R2) | 27.58 | 27.05 | 27.54 | 27.66 | |
Resistance 1 (R1) | 26.81 | 26.72 | 27.20 | 26.74 | 27.54 |
Pivot Point | 26.20 | 26.20 | 26.39 | 26.16 | 26.20 |
Support 1 (S1) | 25.43 | 25.67 | 25.82 | 25.36 | 24.56 |
Support 2 (S2) | 24.82 | 25.34 | 24.78 | 24.44 | |
Support 3 (S3) | 24.05 | 24.82 | 24.33 | ||
Support 4 (S4) | 23.98 |